| Filed | Form | Description | |
|---|---|---|---|
| 1/14/26 | 424B3 | 424B3 | → |
| 12/31/25 | F-3ASR | REGISTRATION STATEMENT | → |
| 12/30/25 | F-3 | REGISTRATION STATEMENT | → |
| 2/12/25 | 424B3 | 424B3 | → |
| 2/6/25 | F-3/A | AMENDMENT NO. 1 TO FORM F-3 | → |
| 2/5/25 | F-3 | REGISTRATION STATEMENT | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 12/16/24 | SC 13G/A | AMENDMENT TO FORM SC 13G | → |
| 10/9/24 | SC 13G/A | AMENDMENT TO FORM SC 13G | → |
| 7/11/24 | SC 13G/A | AMENDMENT TO FORM SC 13G | → |
| 5/3/24 | SC 13G/A | AMENDMENT TO FORM SC 13G | → |
| 4/9/24 | SC 13G/A | AMENDMENT NO. 1 TO SCHEDULE 13G | → |
| 4/3/24 | SC 13G/A | AMENDMENT NO. 3 TO SCHEDULE 13G | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 1/14/26 | EFFECT | EFFECT | → |
| 9/16/25 | SCHEDULE 13G | SCHEDULE 13G | → |
| 9/12/25 | SCHEDULE 13G/A | SCHEDULE 13G/A | → |
| 2/12/25 | EFFECT | EFFECT | → |
| 12/27/24 | EFFECT | EFFECT | → |
| 4/24/24 | EFFECT | EFFECT | → |
| ↓ | |||
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain.